ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
Suven Life Sciences Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report details the company's operational, employee, and ESG metrics.
Suven Life Sciences will present five posters at AAIC-2026 in London, updating its Phase-3 Masupirdine and Phase-2 Usmarapride programs. It seeks partnerships for its CNS pipeline.
Suven Life Sciences reported positive interim safety and analysis results for its Masupirdine Phase 3 study. The trial remains unchanged with enrollment completion expected by September 2026.